Strengthening the Group as a Research and Development-Oriented Company
First written in FY2016. 20 of 33 entries say "Restated". Latest entry: FY2026.
90 other companies' latest entry also says "Other".
- FY2026Full-year R&D expense updateAnnual report
「Group-wide R&D expenses for the consolidated fiscal year were ¥5,920 million.」
The full-year R&D expense result was updated to ¥5,920 million, and R&D into new technologies, new materials and new systems and equipment is continuing across all segments. - FY2026-H1Interim R&D Expense UpdateAnnual report
「Total R&D expenses for the interim consolidated fiscal period were ¥2,889 million. There were no material changes in the status of the Group's R&D activities during the interim consolidated fiscal period.」
It states that there have been no material changes in R&D activities and updates interim R&D expenses to ¥2,889 million. - FY2025Full-year R&D expense updateAnnual report
「Group-wide R&D expenses for the consolidated fiscal year were ¥5,886 million, and the Group plans to continue its activities with a target of around 5% of net sales.」
The full-year R&D expense result was updated to ¥5,886 million, and the policy of targeting around 5% of net sales is being continued. - FY2025-H1Interim R&D Expense UpdateAnnual report
「Total R&D expenses for the interim consolidated fiscal period were ¥2,879 million. There were no material changes in the status of the Group's R&D activities during the interim consolidated fiscal period.」
It discloses interim R&D expenses of ¥2,879 million, stating that there have been no material changes in R&D activities. - FY2024Full-year R&D expense updateAnnual report
「Group-wide R&D expenses for the consolidated fiscal year were ¥5,906 million, and the Group plans to continue its activities with a target of around 5% of net sales.」
R&D expenses were ¥5,906 million, and the policy of targeting around 5% of net sales is being continued. - FY2024-Q3Update to R&D expenses for the first 3 quartersAnnual report
「Total R&D expenses for the cumulative third quarter of the consolidated fiscal year were ¥4,721 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter of the consolidated fiscal year.」
It discloses R&D expenses of ¥4,721 million for the cumulative third quarter, stating that there have been no material changes in R&D activities. - FY2024-Q2Second-quarter R&D expenses updatedAnnual report
「Total R&D expenses for the cumulative second quarter of the consolidated fiscal year were ¥3,061 million. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter of the consolidated fiscal year.」
It discloses R&D expenses of ¥3,061 million for the cumulative second quarter, stating that there have been no material changes in R&D activities. - FY2024-Q1Update to R&D ExpensesAnnual report
「Total R&D expenses for the cumulative first quarter of the consolidated fiscal year were ¥1,329 million. There were no material changes in the status of the Group's R&D activities during the cumulative first quarter of the consolidated fiscal year.」
It discloses R&D expenses of ¥1,329 million for the cumulative first quarter, stating that there have been no material changes in R&D activities. - FY2023Update to R&D ExpensesAnnual report
「Group-wide R&D expenses for the consolidated fiscal year were ¥5,408 million, and the Group plans to continue its activities with a target of around 5% of net sales.」
The company recorded R&D expenses of ¥5,408 million and continues its policy of targeting around 5% of net sales. - FY2023-Q3RestatedAnnual report
「Total R&D expenses for the cumulative third quarter of the consolidated fiscal year were ¥4,029 million. There were no material changes in the status of the Group's R&D activities during the cumulative third quarter of the consolidated fiscal year.」
It discloses R&D expenses of ¥4,029 million for the cumulative third quarter, stating that there have been no material changes in R&D activities. - FY2023-Q1RestatedAnnual report
「Total R&D expenses for the cumulative first quarter of the consolidated fiscal year were ¥1,283 million. There were no material changes in the status of the Group's R&D activities during the cumulative first quarter of the consolidated fiscal year.」
It states that there have been no material changes in R&D activities and reports R&D expenses of ¥1,283 million for the cumulative first quarter. - FY2022Update to R&D ExpensesAnnual report
「Group-wide R&D expenses for the consolidated fiscal year were ¥5,540 million, and the Group plans to continue its activities with a target of around 5% of net sales.」
R&D expenses were ¥5,540 million, and the policy of targeting around 5% of net sales for R&D activities is being continued. - FY2022-Q2RestatedAnnual report
「Total research and development expenses for the cumulative second-quarter period amounted to ¥2,607 million. There were no significant changes in the status of the Group’s research and development activities during the cumulative second-quarter period.」
It states that there have been no material changes in R&D activities and reports R&D expenses of ¥2,607 million for the cumulative second quarter. - FY2022-Q1RestatedAnnual report
「Total research and development expenses for the cumulative first-quarter period amounted to ¥1,178 million. There were no significant changes in the status of the Group’s research and development activities during the cumulative first-quarter period.」
The filing states that there were no significant changes in research and development activities and reports research and development expenses of ¥1,178 million for the cumulative first quarter. - FY2021Update to R&D ExpensesAnnual report
「Group-wide research and development expenses for the consolidated fiscal year amounted to ¥4,643 million, and the Group plans to continue conducting activities with approximately 5% of net sales as a guideline.」
Research and development expenses for the fiscal year amounted to ¥4,643 million, and the company continues its policy of using approximately 5% of net sales as a guideline. - FY2021-Q3RestatedAnnual report
「Total research and development expenses for the cumulative third-quarter period amounted to ¥3,380 million. There were no significant changes in the status of the Group’s research and development activities during the cumulative third-quarter period.」
The filing states that there were no significant changes in research and development activities and reports research and development expenses of ¥3,380 million for the cumulative third quarter. - FY2021-Q2RestatedAnnual report
「Total research and development expenses for the cumulative second-quarter period amounted to ¥2,196 million. There were no significant changes in the status of the Group’s research and development activities during the cumulative second-quarter period.」
The filing states that there were no significant changes in research and development activities and reports research and development expenses of ¥2,196 million for the cumulative second quarter. - FY2021-Q1RestatedAnnual report
「Total research and development expenses for the cumulative first-quarter period amounted to ¥1,150 million. There were no significant changes in the status of the Group’s research and development activities during the cumulative first-quarter period.」
The filing states that there were no significant changes in research and development activities and reports research and development expenses of ¥1,150 million for the cumulative first quarter. - FY2020Update to R&D ExpensesAnnual report
「Group-wide research and development expenses for the consolidated fiscal year amounted to ¥5,049 million, and the Group plans to continue conducting activities with approximately 5% of net sales as a guideline.」
Research and development expenses amounted to ¥5,049 million, and the company continues its policy of using approximately 5% of net sales as a guideline. - FY2020-Q3RestatedAnnual report
「Total research and development expenses for the cumulative third-quarter period amounted to ¥3,839 million. There were no significant changes in the status of the Group’s research and development activities during the cumulative third-quarter period.」
The filing states that there were no significant changes in research and development activities and reports research and development expenses of ¥3,839 million for the cumulative third quarter. - FY2020-Q2RestatedAnnual report
「Total research and development expenses for the cumulative second-quarter period amounted to ¥2,616 million. There were no significant changes in the status of the Group’s research and development activities during the cumulative second-quarter period.」
The filing states that there were no significant changes in research and development activities and reports research and development expenses of ¥2,616 million for the cumulative second quarter. - FY2020-Q1RestatedAnnual report
「Total research and development expenses for the cumulative first-quarter period amounted to ¥1,337 million. There were no significant changes in the status of the Group’s research and development activities during the cumulative first-quarter period.」
The filing states that there were no significant changes in research and development activities and reports research and development expenses of ¥1,337 million for the cumulative first quarter. - FY2019RestatedAnnual report
「Group-wide research and development expenses for the consolidated fiscal year amounted to ¥5,277 million, and the Group plans to continue conducting activities with approximately 5% of net sales as a guideline.」
The company recorded research and development expenses of ¥5,277 million and continues its policy of using approximately 5% of net sales as a guideline. - FY2019-Q3RestatedAnnual report
「Total research and development expenses for the cumulative third-quarter period amounted to ¥3,781 million. There were no significant changes in the status of the Group’s research and development activities during the cumulative third-quarter period.」
The filing states that there were no significant changes in research and development activities and reports research and development expenses of ¥3,781 million for the cumulative third quarter. - FY2019-Q2RestatedAnnual report
「Total research and development expenses for the cumulative second-quarter period amounted to ¥2,438 million. There were no significant changes in the status of the Group’s research and development activities during the cumulative second-quarter period.」
The filing states that there were no significant changes in research and development activities and reports research and development expenses of ¥2,438 million for the cumulative second quarter. - FY2019-Q1RestatedAnnual report
「Total research and development expenses for the cumulative first-quarter period amounted to ¥1,267 million. There were no significant changes in the status of the Group’s research and development activities during the cumulative first-quarter period.」
The filing states that there were no significant changes in research and development activities and reports research and development expenses of ¥1,267 million for the cumulative quarter. - FY2018-Q3RestatedAnnual report
「Total research and development expenses for the cumulative third-quarter period amounted to ¥3,710 million. There were no significant changes in the status of the Group’s research and development activities during the cumulative third-quarter period.」
The filing states that there were no significant changes in research and development activities and reports research and development expenses of ¥3,710 million for the cumulative third quarter. - FY2018-Q2RestatedAnnual report
「Total research and development expenses for the cumulative second-quarter period amounted to ¥2,473 million. There were no significant changes in the status of the Group’s research and development activities during the cumulative second-quarter period.」
The filing states that there were no significant changes in research and development activities and reports research and development expenses of ¥2,473 million for the cumulative second quarter. - FY2018-Q1RestatedAnnual report
「Total research and development expenses for the cumulative first-quarter period amounted to ¥1,263 million. There were no significant changes in the status of the Group’s research and development activities during the cumulative first-quarter period.」
The filing states that there were no significant changes in research and development activities and reports research and development expenses of ¥1,263 million for the cumulative first quarter. - FY2017-Q3RestatedAnnual report
「Total research and development expenses for the cumulative third-quarter period amounted to ¥3,809 million. There were no significant changes in the status of the Group’s research and development activities during the cumulative third-quarter period.」
The filing states that there were no significant changes in research and development activities and reports research and development expenses of ¥3,809 million for the cumulative third quarter. - FY2017-Q2RestatedAnnual report
「Total research and development expenses for the cumulative second-quarter period amounted to ¥2,565 million. There were no significant changes in the status of the Group’s research and development activities during the cumulative second-quarter period.」
The filing states that there were no significant changes in research and development activities and reports research and development expenses of ¥2,565 million for the cumulative quarter. - FY2017-Q1RestatedAnnual report
「Total research and development expenses for the cumulative first-quarter period amounted to ¥1,227 million. There were no significant changes in the status of the Group’s research and development activities during the cumulative first-quarter period.」
The filing states that there were no significant changes in research and development activities and reports research and development expenses of ¥1,227 million for the quarter. - FY2016First statedAnnual report
「Strengthening the Group as a research and development-oriented company: actively investing in technology, equipment and software development and creating an environment that supports these activities.」
The Group is developing new technologies, materials, systems and equipment across all segments. Research and development expenses were ¥5,483 million, and the Group intends to continue using approximately 5% of net sales as a benchmark.